LUCIRA™ HEALTH COVID-19 Test Approved for Sale in Singapore
October 12 2021 - 7:00AM
Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a
medical technology company focusing on the development and
commercialization of transformative and innovative infectious
disease test kits, received PSAR approval for its LUCIRA CHECK IT
COVID-19 Test Kit by Singapore's Health Sciences Authority.
Lucira's test kit provides lab quality molecular results
on-the-spot within 30 minutes.
Chief Revenue Officer Kevin Collins added, "Approval in
Singapore is an important step in Lucira's continued international
commercial expansion. We are grateful for the work that Singapore's
Health Sciences Authority performed in evaluating our test kit and
are appreciative of our partnership with the Labgistics team. We
look forward to our easy-to-use and accurate test kit being an
important tool in Singapore's effort to control COVID-19 among its
population and visitors."
Additionally, Labgistics Asia Pte Ltd General Manager, Roy Wong
commented, "Singapore continues to incorporate new fast and easy
tests into the approved list of self-tests with the LUCIRA CHECK IT
COVID-19 Test Kit being the latest approval via the Pandemic
Special Access Route. Lucira Health's test kit is the only approved
self-test in Singapore that is based on the gold standard molecular
technology. Despite reporting that 82% of the population has been
fully vaccinated, testing remains an important component in the
overall strategy, and we are delighted to have worked with Lucira
Health and will continue to work closely with both Lucira Health
and local authorities on how this test can contribute to the
overall testing strategy."Erik Engelson, Lucira Health's President
& CEO remarked, "We see the importation and use of the Lucira
test kit in Singapore as an important commercial step for Lucira.
We appreciate our partnership with Labgistics, as well as the
leadership by Lucira's Commercial and Regulatory Affairs teams that
led to this opportunity. Geographic expansion is one of several key
growth strategies for Lucira along with test menu expansion beyond
COVID-19 on our adaptable platform."
About Lucira Health
Lucira is a medical technology company focused on the
development and commercialization of transformative and innovative
infectious disease test kits. Lucira's testing platform produces
lab quality molecular testing in a single-use, consumer-friendly,
palm-size test kit powered by two AA batteries. Lucira designed its
test kits to provide accurate, reliable, and on-the-spot molecular
test results anywhere and at any time. The LUCIRA™ CHECK IT
COVID-19 Test Kit (OTC) and LUCIRA™ COVID-19 All-In-One Test Kit
(Rx) are designed to provide a clinically relevant COVID-19 result
within 30 minutes from sample collection. For more information,
visit www.lucirahealth.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, Lucira's continued development and
commercialization of its transformative and innovative infectious
disease test kits and ability to increase sales. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Words such as "can," "plans," "will,"
"may," "anticipates," "expects," "potential," and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Lucira's current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results could differ materially
from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, including our ability to
increase production, streamline operations and increase product
availability; the success of our test platform with COVID-19, the
impact to our business of the ongoing COVID-19 pandemic; our
ability to successfully continue to expand internationally; any
impact on our ability to market our products; demand for our
products due to deferral of procedures using our products or
disruption in our supply chain; our ability to achieve or sustain
profitability; our ability to gain market acceptance for our
products and to accurately forecast and meet customer demand; our
ability to compete successfully; our ability to enhance our product
offerings; development and manufacturing problems; capacity
constraints or delays in production of our products; maintenance of
coverage and adequate reimbursement for procedures using our
products; and product defects or failures. These and other risks
and uncertainties are described more fully in the "Risk Factors"
section and elsewhere in our filings with the Securities and
Exchange Commission and available at www.sec.gov,
including in our most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q. Any forward-looking statements that
we make in this announcement speak only as of the date of this
press release, and Lucira assumes no obligation to update
forward-looking statements whether as a result of new information,
future events or otherwise after the date of this press release,
except as required under applicable law.
Media ContactKevin
Knightmedia@lucirahealth.com206-451-4823
Investor ContactGreg
ChodaczekInvestorrelations@lucirahealth.com347-620-7010
Lucira Health (NASDAQ:LHDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lucira Health (NASDAQ:LHDX)
Historical Stock Chart
From Sep 2023 to Sep 2024